Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxycillin + dicloxacillin + lactic acid bacillus
- Development stage
- Unknown
- Lead developer
- Sai Sarvaa Biotech
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Amoxycillin + dicloxacillin + lactic acid bacillus is a fixed-dose combination medication containing two penicillin-class antibiotics (amoxycillin and dicloxacillin) and a probiotic (lactic acid bacillus, also known as Lactobacillus). Amoxycillin is a broad-spectrum semi-synthetic penicillin that inhibits bacterial cell wall synthesis. Dicloxacillin is a penicillinase-resistant penicillin that is highly active against penicillinase-producing Gram-positive bacteria, such as Staphylococcus aureus, thereby protecting amoxycillin from enzymatic degradation. Lactic acid bacillus is a probiotic that helps restore and maintain healthy gut microflora, reducing the risk of antibiotic-associated diarrhea. This combination is approved and used for the treatment of various bacterial infections, including respiratory tract, urinary tract, skin, ear, and soft tissue infections.
- Brand names
- AMOLINE DXAmyvoxAramox DBrucloxDiamox LBEasymox LBExodox-LBFayo Dox LBIifamox DCKiwimox DXMahamox LB PlusMonomax-DXMonomox DXMoxizest LBMoxy-DNovaclox-LBRELIN-D PLUSSimplemox LBStaphacillin BSTresmox LB DTresmox-LB D
- Other names
- amoxicillin + dicloxacillin + lactic acid bacillusamoxicillin + dicloxacillin + lactobacillusamoxycillin + dicloxacillin + lactobacillus
02
Targets
PBPs (Staphylococcal penicillin-binding proteins)PBP1A (Penicillin-binding protein 1A)
Beyond the preview
Go deeper on amoxycillin + dicloxacillin + lactic acid bacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxycillin + dicloxacillin + lactic acid bacillus.